Former Siga CFO Tom Konatich testified today that Siga originally contacted PharmAthene and offered to license Siga’s smallpox drug, ST-246, because Siga needed to improve its cash flow quickly.  But in response, according to Mr. Konatich, PharmAthene told him that they were not interested in a license arrangement, and that “it was a merger or nothing.”

Mr. Konatich also testified that later a licensing agreement was considered as a quick first step towards an eventual merger.

CVN is webcasting PharmAthene v. Siga live.